Skip to main content
. 2024 May 24;8(15):3859–3869. doi: 10.1182/bloodadvances.2023012470

Figure 1.

Figure 1.

Survival analysis according to ALC and other disease features. PFS by ALCmax (A), presence of high-risk cytogenetics (any of deletion 17p, t(4;14), t(14;16) or gain 1q) (B), and presence of nonparaskeletal EMD (non-PS EMD) (C) subgroups in the BCMA CAR-T cohort. PFS in patients treated with cilta-cel (D) and ide-cel (E).